How to translate text using browser tools
4 February 2019 Clinical application of embryo aneuploidy testing by next-generation sequencing
Carmen Rubio, Lorena Rodrigo, Carmen Garcia-Pascual, Vanessa Peinado, Inmaculada Campos-Galindo, Sandra Garcia-Herrero, Carlos Simón
Author Affiliations +
Abstract

We review here the evolution in the field of embryo aneuploidy testing over the last 20 years, from the analysis of a subset of chromosomes by fluorescence in situ hybridisation to the transition toward a more comprehensive analysis of all 24 chromosomes. This current comprehensive aneuploidy testing most commonly employs next-generation sequencing (NGS). We present our experience in over 130 000 embryo biopsies using this technology. The incidence of aneuploidy was lower in trophectoderm biopsies compared to cleavage-stage biopsies. We also confirmed by NGS that embryo aneuploidy rates increased with increasing maternal age, mostly attributable to an increase in complex aneuploid embryos. In contrast, the number of MII oocytes retrieved or the use of oocyte vitrification did not affect aneuploidy rates. Similarly, neither maternal age, oocyte number, nor oocyte vitrification affected the incidence of mosaicism. Analysis of clinical outcomes, indications, and potential benefits of embryo aneuploidy testing revealed advanced maternal age as the most favored group, with some evidence of improved delivery rate per transfer as well as decreased miscarriage rates and time to pregnancy. Other indications are: recurrent miscarriage, repetitive implantation failure, severe male factor, previous trisomic pregnancy, and good prognosis patients mainly undergoing single embryo transfer, with the latter indication used to reduce the occurrence of multiple pregnancies without compromising cycle outcome. In conclusion, NGS has become the most appropriate technology for aneuploidy testing in trophectoderm biopsies, with accurate results, high throughput, and cost efficiency. This technology can be also applied to the analysis of the embryonic cell free DNA released to the culture media at blastocyst stage. This is a promising approach towards a non-invasive preimplantation genetic testing of aneuploidy.

Summary Sentence

NGS has become the most appropriate technology to apply for aneuploidy testing in trophectoderm biopsies, offering accurate results with a high throughput and cost efficiency.

© The Author(s) 2019. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Carmen Rubio, Lorena Rodrigo, Carmen Garcia-Pascual, Vanessa Peinado, Inmaculada Campos-Galindo, Sandra Garcia-Herrero, and Carlos Simón "Clinical application of embryo aneuploidy testing by next-generation sequencing," Biology of Reproduction 101(6), 1083-1090, (4 February 2019). https://doi.org/10.1093/biolre/ioz019
Received: 13 August 2018; Accepted: 3 February 2019; Published: 4 February 2019
KEYWORDS
aneuploidy
blastocyst
embryo
NGS
trophectoderm biopsy
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top